The Drug Development Paradigm in Oncology Proceedings of a Workshop
Afbeeldingen
Sla de afbeeldingen overArtikel vergelijken
Samenvatting
Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of efforts?by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)?to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop. Table of Contents Front Matter Proceedings of a Workshop Appendix A: Statement of Task Appendix B: Workshop Agenda
Productspecificaties
Wij vonden geen specificaties voor jouw zoekopdracht '{SEARCH}'.
Inhoud
- Taal
- en
- Bindwijze
- Paperback
- Oorspronkelijke releasedatum
- 12 maart 2018
- Aantal pagina's
- 144
- Illustraties
- Met illustraties
Betrokkenen
- Tweede Auteur
- Health And Medicine Division
- Co Auteur
- National Cancer Policy Forum
- Hoofdredacteur
- Sharyl J. Nass
- Hoofduitgeverij
- National Academies Press
Overige kenmerken
- Extra groot lettertype
- Nee
- Studieboek
- Ja
- Verpakking breedte
- 152 mm
- Verpakking hoogte
- 229 mm
- Verpakking lengte
- 229 mm
EAN
- EAN
- 9780309457941
Je vindt dit artikel in
- Categorieën
- Taal
- Engels
- Studieboek of algemeen
- Studieboeken
- Boek, ebook of luisterboek?
- Boek
Kies gewenste uitvoering
Bindwijze
: Paperback
Prijsinformatie en bestellen
Rapporteer dit artikel
Je wilt melding doen van illegale inhoud over dit artikel:
- Ik wil melding doen als klant
- Ik wil melding doen als autoriteit of trusted flagger
- Ik wil melding doen als partner
- Ik wil melding doen als merkhouder
Geen klant, autoriteit, trusted flagger, merkhouder of partner? Gebruik dan onderstaande link om melding te doen.